Skip to main content
SLU publication database (SLUpub)

Research article2022Peer reviewedOpen access

An inverse association between plasma benzoxazinoid metabolites and PSA after rye intake in men with prostate cancer revealed with a new method

Nordin, Elise; Steffensen, Stine K.; Laursen, Bente B.; Andersson, Sven-Olof; Johansson, Jan-Erik; Aman, Per; Hallmans, Goran; Borre, Michael; Staerk, Dan; Hanhineva, Kati; Fomsgaard, Inge S.; Landberg, Rikard

Abstract

Prostate cancer (PC) is a common cancer among men, and preventive strategies are warranted. Benzoxazinoids (BXs) in rye have shown potential against PC in vitro but human studies are lacking. The aim was to establish a quantitative method for analysis of BXs and investigate their plasma levels after a whole grain/bran rye vs refined wheat intervention, as well as exploring their association with PSA, in men with PC. A quantitative method for analysis of 22 BXs, including novel metabolites identified by mass spectrometry and NMR, was established, and applied to plasma samples from a randomized crossover study where patients with indolent PC (n = 17) consumed 485 g whole grain rye/rye bran or fiber supplemented refined wheat daily for 6 wk. Most BXs were significantly higher in plasma after rye (0.3-19.4 nmol/L in plasma) vs. refined wheat (0.05-2.9 nmol/L) intake. HBOA-glc, 2-HHPAA, HBOA-glcA, 2-HPAA-glcA were inversely correlated to PSA in plasma (p < 0.04). To conclude, BXs in plasma, including metabolites not previously analyzed, were quantified. BX metabolites were significantly higher after rye vs refined wheat consumption. Four BX-related metabolites were inversely associated with PSA, which merits further investigation.

Published in

Scientific Reports
2022, Volume: 12, article number: 5260
Publisher: NATURE PORTFOLIO

    UKÄ Subject classification

    Nutrition and Dietetics
    Clinical Laboratory Medicine

    Publication identifier

    DOI: https://doi.org/10.1038/s41598-022-08856-z

    Permanent link to this page (URI)

    https://res.slu.se/id/publ/116837